Combination therapy for Type 2 diabetes: repaglinide plus rosiglitazone

Aims  This 24‐week, randomized, multicentre, open‐label, parallel‐group clinical trial compared efficacy and safety of repaglinide monotherapy, rosiglitazone monotherapy, and combination therapy (repaglinide plus rosiglitazone) in Type 2 diabetes after unsatisfactory response to sulphonylurea or metformin monotherapy.

[1]  Robert M. Anderson,et al.  Prevention or delay of type 2 diabetes. , 2004, Diabetes care.

[2]  INCREMENTAL METHODS OF IMPUTATION IN LONGITUDINAL CLINICAL TRIALS , 2002 .

[3]  D. Erkelens,et al.  Insulin resistance syndrome and type 2 diabetes mellitus. , 2001, The American journal of cardiology.

[4]  D. Betteridge.  Dyslipidaemia and diabetes , 2001 .

[5]  M. Feinglos,et al.  Oral agents in the management of type 2 diabetes mellitus. , 2001, American family physician.

[6]  S. Mudaliar,et al.  New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. , 2001, Annual review of medicine.

[7]  P. Raskin,et al.  Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes. , 2000, Diabetes care.

[8]  P. Clauson,et al.  A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. , 1999, Diabetes care.

[9]  S. Colagiuri,et al.  Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. , 1999, Diabetes care.

[10]  R. Goldberg,et al.  Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes. , 1999, Diabetes technology & therapeutics.

[11]  Nicollerat Ja.  Implications of the United Kingdom Prospective Diabetes Study , 1998, Diabetes Care.

[12]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[13]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[14]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.